Product
BCX9930
Aliases
BCX9930 monotherapy
5 clinical trials
5 indications
Indication
Paroxysmal Nocturnal HemoglobinuriaIndication
PNHIndication
C3 GlomerulopathyIndication
IgA NephropathyIndication
Membranous NephropathyClinical trial
An Open-label Study to Evaluate the Long-term Safety of BCX9930 Monotherapy in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Previously Received BCX9930 in a BioCryst-sponsored StudyStatus: Active (not recruiting), Estimated PCD: 2026-02-01
Clinical trial
A Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor TherapyStatus: Terminated, Estimated PCD: 2023-09-14
Clinical trial
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of PNHStatus: Terminated, Estimated PCD: 2023-09-14
Clinical trial
A Phase 2, Open-Label Study to Evaluate the Long-term Safety of Oral BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)Status: Terminated, Estimated PCD: 2023-10-04
Clinical trial
An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects With Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous NephropathyStatus: Terminated, Estimated PCD: 2022-09-23